COLOMBO NICOLETTA

De Vitis, L., Schivardi, G., Gaeta, A., Caruso, G., Rosanu, M., Ribero, L., et al. (2025). External validation of the Annual Recurrence Risk Model (ARRM) for tailored surveillance strategy in patients with cervical cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER [10.1016/j.ijgc.2025.101756]. Detail

Lorusso, D., Colombo, N., Dubot, C., Cáceres, M., Hasegawa, K., Shapira-Frommer, R., et al. (2025). Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. ANNALS OF ONCOLOGY, 36(1), 65-75 [10.1016/j.annonc.2024.10.002]. Detail

Quesada, S., Penault-Llorca, F., Matias-Guiu, X., Banerjee, S., Barberis, M., Coleman, R., et al. (2025). Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics. EUROPEAN JOURNAL OF CANCER, 215(17 January 2025) [10.1016/j.ejca.2024.115169]. Detail

Oaknin, A., Monk, B., de Melo, A., Kim, H., Kim, Y., Lisyanskaya, A., et al. (2025). Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. EUROPEAN JOURNAL OF CANCER, 216(5 February 2025) [10.1016/j.ejca.2024.115146]. Detail

Bogani, G., Moore, K., Ray-Coquard, I., Lorusso, D., Matulonis, U., Ledermann, J., et al. (2025). Incorporating immune checkpoint inhibitors in epithelial ovarian cancer. GYNECOLOGIC ONCOLOGY, 193(February 2025), 30-40 [10.1016/j.ygyno.2024.12.011]. Detail